Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

Date : 12/06/2019 @ 9:01PM
Source : GlobeNewswire Inc.
Stock : Cara Therapeutics Inc (CARA)
Quote : 16.05  -0.29 (-1.77%) @ 4:59AM
Cara Therapeutics share price Chart
After Hours
Last Trade
Last $ 16.05 ◊ 0.00 (0.00%)

Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan

Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Cara Therapeutics Charts.

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Compensation Committee of Cara’s Board of Directors has approved the grant of non-qualified stock options to purchase an aggregate of 47,500 shares of common stock, to be distributed among two new non-executive employees, pursuant to Cara’s 2019 Inducement Plan.

The awards have a grant date of December 2, 2019 and an exercise price of $25.88 per share, which is equal to the closing price of Cara’s common stock on the date of grant. In each case, 25% of the shares underlying the options will vest on the first anniversary of the date of grant, with the remainder vesting in 36 equal monthly installments over the subsequent three-year period, in all cases contingent on such employee’s continued service with Cara on the applicable vesting date.

The stock options were granted as inducement material to each new employee entering into employment with Cara in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system, and on immune cells. In a Phase 3 and two Phase 2 trials, KORSUVA (CR845/difelikefalin) Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP), and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis (PBC).

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 astarr@6degreespr.com

INVESTOR CONTACT: Jane Urheim Stern Investor Relations, Inc. 212-362-1200 jane.urheim@sternir.com

Latest CARA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200126 09:48:16